Abstract Background and aims Endothelial dysfunction is critical in diabetic angiopathy. While our previous study established role of FOXO1 in mediating advanced glycation end products (AGEs)-induced autophagic apoptosis in human aortic endothelial cells (HAECs), the potential mechanism of N6-methyladenosine (m 6 A) modification in this process remains unknown. Methods RNA-m 6 A methylation and methyltransferase-like 3 (METTL3) / YTH domain containing 1 (YTHDC1) expression in carotid plaques of diabetic patients and aortic plaques of diabetic apoe −/− mice induced by STZ were detected by quantitative kit, immunohistochemical staining and immunofluorescence co-localization respectively. METTL3 and YTHDC1 were knocked down to observe changes in the m 6 A methylation status and expression of FOXO1. FOXO1 was overexpressed in METTL3-deficient HAECs to assess autophagic flux and apoptosis. Finally, the effect of METTL3 on atherosclerotic plaque formation was validated using endothelial cell-specific METTL3 knockout diabetic mice. Results RNA m 6 A modification levels and the expression of the METTL3/YTHDC1 were upregulated in human diabetic carotid plaques, mouse aortic plaques, and AGEs-treated HAECs, accompanied by increased m 6 A methylation of Foxo1 mRNA. METTL3 mediates the AGEs-induced increase in m 6 A modification of Foxo1 mRNA, which is subsequently recognized by the YTHDC1 at a specific site in the 3’-UTR-3. This mechanism synergistically enhances FOXO1 expression and blocks autophagic flux leading to apoptosis in endothelial cells. In vivo, endothelial-specific METTL3 knockout attenuated aortic plaque formation in diabetic atherosclerotic mice and reduced FOXO1 expression along with autophagic apoptosis related proteins. Conclusions The METTL3/YTHDC1 axis-mediated m 6 A modification of Foxo1 mRNA promotes endothelial autophagic apoptosis in diabetic atherosclerosis, revealing a promising therapeutic target.
Zhao et al. (Thu,) studied this question.